Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...

Opdivo is the first and only PD-1 inhibitor to demonstrate superior overall survival and progression-free survival in combination with chemotherapy when compared to chemotherapy alone in patients with ...

Other Participants in the Round Include Kevin Johnson (former CEO of Ebates at Rakuten), f7 Ventures, Blackbird Ventures, Scribble Ventures, Hyper and Susa Ventures SAN FRANCISCO--(BUSINESS ...

Thierry André and colleagues recently reported that nivolumab–ipilimumab provided an impressive absolute progression-free survival benefit at 36 months, which was 17% compared with nivolumab ...

This week, drug maker Bristol-Myers Squibb announced in a press release that the ongoing Phase 3 Checkmate-227 trial met its co-primary endpoint of progression-free survival with Opdivo plus Yervoy ...

Nivolumab failed to perform better than chemotherapy in patients with squamous as well as non-squamous non-small cell lung cancer (NSCLC). Bristol Myer Squibb (BMS)’s recent immunotherapy success, ...